Syndrome-associated soft tissue tumours

Histopathology

Volumn 64, Issue 1, 2014, Pages 68-87

  Coffin, Cheryl M ^a   Davis, Jessica L ^b   Borinstein, Scott C ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Desmoid type fibromatosis; Gardner fibroma; Li Fraumeni syndrome; Malignant peripheral nerve sheath tumour; Malignant rhabdoid tumour; Neurofibroma; Neurofibromatosis type I; Rhabdomyosarcoma; Schwannoma

Indexed keywords

BETA CATENIN; CD99 ANTIGEN; CLAUDIN 1; COLLAGEN TYPE 4; DICER; EPITHELIAL MEMBRANE ANTIGEN; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUCOSE TRANSPORTER 1; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; MERLIN; MYOGENIN; NEUROFIBROMIN; NIBRIN; P CADHERIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN PATCHED 1; PROTEIN S 100; PROTEIN TYROSINE PHOSPHATASE SHP 2; RAS PROTEIN; SMOOTH MUSCLE ACTIN; SYNAPTOPHYSIN; TUBERIN; WERNER SYNDROME PROTEIN;

BASAL CELL NEVUS SYNDROME; BECKWITH WIEDEMANN SYNDROME; BLOOM SYNDROME; CANCER SUSCEPTIBILITY; CARNEY COMPLEX; COLON POLYPOSIS; COSTELLO SYNDROME; DESMOID TUMOR; DISEASE ASSOCIATION; EMBRYONAL RHABDOMYOSARCOMA; FAMILY HISTORY; FIBROMATOSIS; GARDNER SYNDROME; GENE MUTATION; GLOMUS TUMOR; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LEIOMYOMATOSIS; LYMPHANGIOMA; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; NEURILEMOMA; NEUROFIBROMA; NEUROFIBROMATOSIS; PATHOLOGIST; PRIORITY JOURNAL; RETINOBLASTOMA; REVIEW; RHABDOID TUMOR; RHABDOMYOSARCOMA; RUBINSTEIN SYNDROME; SOFT TISSUE TUMOR; TUBEROUS SCLEROSIS; WERNER SYNDROME;

DESMOID-TYPE FIBROMATOSIS; GARDNER FIBROMA; LI-FRAUMENI SYNDROME; MALIGNANT PERIPHERAL NERVE SHEATH TUMOUR; MALIGNANT RHABDOID TUMOUR; NEUROFIBROMA; NEUROFIBROMATOSIS TYPE I; RHABDOMYOSARCOMA; SCHWANNOMA;

HUMANS; SOFT TISSUE NEOPLASMS; SYNDROME;

EID: 84889877816     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12280     Document Type: Review

References (203)

1. Coffin CM, Alaggio R, Dehner LP. Some general considerations about the clinicopathologic aspects of soft tissue tumors in children and adolescents. Pediatr. Dev. Pathol. 2012; 15; 11-25.
2. Bridge JA, Mertens F. Tumour syndromes: introduction. In Fletcher CDM, Bridge JA, Hogendoorn PCW, Merterns F eds. WHO classification of tumours of soft tissue and bone, 4th edn. Lyon, France: International Agency for Research on Cancer, 2013; 368-371.
3. Agha MM, Williams JI, Marrett L et al. Congenital abnormalities and childhood cancer. Cancer 2005; 103; 1939-1948.
4. D'Orazio JA. Inherited cancer syndromes in children and young adults. J. Pediatr. Hematol. Oncol. 2010; 32; 195-228.
5. Garber JE, Offit K. Hereditary cancer predisposition syndromes. J. Clin. Oncol. 2005; 23; 276-292.
6. Hartley AL, Birch JM, Blair V et al. Patterns of cancer in the families of children with soft tissue sarcoma. Cancer 1993; 72; 923-930.
7. Burningham Z, Hashibe M, Spector L et al. The epidemiology of sarcoma. Clin. Sarcoma Res. 2012; 2; 14.
8. Lindor NM, McMaster ML, Lindor CJ, Greene MH. Concise handbook of familial cancer susceptibility syndromes, 2nd edn. J. Natl Cancer Inst. Monogr. 2008; 38; 1-93.
9. Merimsky O, Kollender Y, Issakov J et al. Multiple primary malignancies in association with soft tissue sarcomas. Cancer 2001; 91; 1363-1371.
10. Merks JHM, Caron HN, Hennekam RCM. High incidence of malformation syndromes in a series of 1, 073 children with cancer. Am. J. Med. Genet. 2005; 134A; 132-143.
11. Pakakasama S, Tomlinson GE. Genetic predisposition and screening in pediatric cancer. Pediatr. Clin. North Am. 2002; 49; 1393-1413.
12. Ross JA, Davies SM. Childhood cancer etiology: recent reports. Med. Pediatr. Oncol. 2001; 37; 55-58.
13. Slater O, Shipley J. Clinical relevance of molecular genetics to pediatric sarcomas. J. Clin. Pathol. 2007; 60; 1187-1194.
14. Spunt SL, Skapek SX, Coffin CM. Pediatric nonrhabdomyosarcoma soft tissue sarcomas. Oncologist 2008; 13; 668-678.
15. Strahm B, Malkin D. Hereditary cancer predisposition in children: genetic basis and clinical implications. Int. J. Cancer 2006; 119; 2001-2006.
16. Howlader N, Noone AM, Krapcho M et al. (eds). SEER cancer statistics review, 1975-2010, National Cancer Institute, Bethesda, MD, http://seer.cancer.gov/csr/1975_2010/based on November 2012 SEER data submission posted to the SEER website, April, 2013. Accessed May 1, 2013.
17. Tischkowitz M, Rosser E. Inherited cancer in children: practical/ethical problems and challenges. Eur. J. Cancer 2004; 40; 2459-2470.
18. Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann. Intern. Med. 1969; 71; 747-752.
19. Li FP, Fraumeni JF Jr, Mulvihill JJ et al. A cancer family syndrome in twenty-four kindreds. Cancer Res. 1988; 48; 5358-5362.
20. Li FP, Abramson DH, Tarone RE et al. Hereditary retinoblastoma, lipoma, and second primary cancers. J. Natl Cancer Inst. 1997; 89; 83-84.
21. Chompret A, Brugieres L, Ronsin M et al. P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br. J. Cancer 2000; 82; 1932-1937.
22. Frebourg T, Barbier N, Yan YX et al. Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome. Am. J. Hum. Genet. 1995; 56; 608-615.
23. Hwang SJ, Lozano G, Amos CI et al. Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. Am. J. Hum. Genet. 2003; 72; 975-983.
24. Malkin D, Jolly KW, Barbier N et al. Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. N. Engl. J. Med. 1992; 326; 1309-1315.
25. Nichols KE, Malkin D, Garber JE et al. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol. Biomark. Prev. 2001; 10; 83-87.
26. Strong LC, Williams WR, Tainsky MA. The Li-Fraumeni syndrome: from clinical epidemiology to molecular genetics. Am. J. Epidemiol. 1992; 135; 190-199.
27. Toguchida J, Yamaguchi T, Dayton SH et al. Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. N. Engl. J. Med. 1992; 326; 1301-1308.
28. Narita T, Dobashi Y, Nakamura T et al. Familial aggregation of soft tissue sarcomas: a report of three cases from a Li-Fraumeni-like family. Arch. Pathol. Lab. Med. 1997; 121; 493-498.
29. Draper GJ, Sanders BM, Kingston JE. Second primary neoplasms in patients with retinoblastoma. Br. J. Cancer 1986; 53; 661-671.
30. Birch JM, Hartley AL, Blair V et al. Cancer in the families of children with soft tissue sarcoma. Cancer 1990; 66; 2239-2248.
31. Jett K, Friedman JM. Clinical and genetic aspects of neurofibromatosis 1. Genet. Med. 2010; 12; 1-11.
32. Online Mendelian Inheritance in Man, OMIM. McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, MD) (9 May 2013). World Wide Web URL: http://omim.org/
33. Lynch HT, Deters CA, Hogg D et al. Familial sarcoma: challenging pedigrees. Cancer 2003; 98; 1947-1957.
34. Dehner LP, Watterson J, Priest J. Pleuropulmonary blastoma: a unique intrathoracic-pulmonary neoplasm of childhood. Perspect. Pediatr. Pathol. 1995; 18; 214-226.
35. Priest JR, Watterson J, Strong L et al. Pleuropulmonary blastoma: a marker of familial disease. J. Pediatr. 1996; 128; 220-224.
36. Oudjik L, Gaal J, Korpershoek E et al. SDHA mutations in adult and pediatric wild-type gastrointestinal stromal tumors. Mod. Pathol. 2013; 26; 456-463.
37. Gordon PL, Wilroy S, Lasater OE et al. Neoplasms in proteus syndrome. Am. J. Med. Genet. 1995; 57; 74-78.
38. Yang P, Grufferman S, Khoury MJ et al. Association of childhood rhabdomyosarcoma with neurofibromatosis type 1 and birth defects. Genet. Epidemiol. 1995; 12; 467-474.
39. Parham DM, Alaggio R, Coffin CM. Myogenic tumors in children and adolescents. Pediatr. Dev. Pathol. 2012; 15; 211-238.
40. Parham DM, Barr FG. Embryonal rhabdomyosarcoma. In Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F eds. WHO classification of tumours of soft tissue and bone, 4th edn. Lyon, France: International Agency for Research on Cancer, 2013; 127-129.
41. Parham DM, Barr FG. Alveolar rhabdomyosarcoma. In Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F eds. WHO classification of tumours of soft tissue and bone, 4th edn. Lyon, France: International Agency for Research on Cancer, 2013; 130-132.
42. Nascimento AF, Barr FG. Spindle cell/sclerosing rhabdomyosarcoma. In Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F eds. WHO classification of tumours of soft tissue and bone, 4th edn. Lyon, France: International Agency for Research on Cancer, 2013; 134-135.
43. Montgomery EA, Barr FG. Pleomorphic rhabdomyosarcoma. In Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F eds. WHO classification of tumours of soft tissue and bone, 4th edn. Lyon, France: International Agency for Research on Cancer, 2013; 132-133.
44. Williamson D, Missiaglia E, de Reynies A et al. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J. Clin. Oncol. 2010; 28; 2151-2158.
45. Wachtel M, Runge T, Leuschner I et al. Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry. J. Clin. Oncol. 2006; 24; 816-822.
46. Grass B, Wachtel M, Behnke S et al. Immunohistochemical detection of EGFR, fibrillin-2, P-cadherin and AP2beta as biomarkers for rhabdomyosarcoma diagnostics. Histopathology 2009; 54; 873-879.
47. Smith AC, Squire JA, Thorner P et al. Association of alveolar rhabdomyosarcoma with the Beckwith-Wiedemann syndrome. Pediatr. Dev. Pathol. 2001; 4; 550-558.
48. Choufani S, Shuman C, Weksberg R. Beckwith-Wiedemann syndrome. Am. J. Med. Genet. C Semin. Med. Genet. 2010; 154C; 343-354.
49. Gripp KW, Scott CI Jr, Nicholson L et al. Five additional Costello syndrome patients with rhabdomyosarcoma: proposal for a tumor screening protocol. Am. J. Med. Genet. 2002; 108; 80-87.
50. Aoki Y, Niihori T, Kawame H et al. Germline mutations in HRAS protooncogene cause Costello syndrome. Nat. Genet. 2005; 37; 1038-1040.
51. Kerr B, Delrue MA, Sigaudy S et al. Genotype-phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases. J. Med. Genet. 2006; 43; 401-405.
52. Kratz CP, Rapisuwon S, Reed H et al. Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes. Am. J. Med. Genet. C Semin. Med. Genet. 2011; 157; 83-89.
53. Sinico M, Bassez G, Touboul C et al. Excess of neuromuscular spindles in a fetus with Costello syndrome: a clinicopathological report. Pediatr. Dev. Pathol. 2011; 14; 218-223.
54. McKeen EA, Bodurtha J, Meadows AT et al. Rhabdomyosarcoma complicating multiple neurofibromatosis. J. Pediatr. 1978; 93; 992-993.
55. Xu GF, O'Connell P, Viskochil D et al. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell 1990; 62; 599-608.
56. Matsui I, Tanimura M, Kobayashi N et al. Neurofibromatosis type 1 and childhood cancer. Cancer 1993; 72; 2746-2754.
57. Reich S, Overberg-Schmidt US, Leenen A et al. Neurofibromatosis 1 associated with embryonal rhabdomyosarcoma of the urinary bladder. Pediatr. Hematol. Oncol. 1999; 16; 263-266.
58. Coffin CM, Cassity J, Viskochil D et al. Non-neurogenic sarcomas in four children and young adults with neurofibromatosis type 1. Am. J. Med. Genet. 2004; 127A; 40-43.
59. Hill DA, Ivanovich J, Priest JR et al. DICER1 mutations in familial pleuropulmonary blastoma. Science 2009; 325; 965.
60. Foulkes WD, Bahubeshi A, Hamel N et al. Extending the phenotypes associated with DICER1 mutations. Hum. Mutat. 2011; 32; 1381-1384.
61. Diller L, Sexsmith E, Gottlieb A et al. Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma. J. Clin. Invest. 1995; 95; 1606-1611.
62. Zahm SH, Fraumeni JF Jr. The epidemiology of soft tissue sarcoma. Semin. Oncol. 1997; 24; 504-514.
63. Khayat CM, Johnston DL. Rhabdomyosarcoma, osteosarcoma, and adrenocortical carcinoma in a child with a germline p53 mutation. Pediatr. Blood Cancer 2004; 43; 683-686.
64. Curry S, Ibrahim F, Grehan D et al. Rhabdomyosarcoma-associated renal cell carcinoma: a link with constitutional TP53 mutation. Pediatr. Dev. Pathol. 2011; 14; 248-251.
65. Mai PL, Malkin D, Garber JE et al. Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium. Cancer Genet. 2012; 205; 479-487.
66. Gorlin RJ. Nevoid basal cell carcinoma syndrome. Dermatol. Clin. 1995; 13; 113-125.
67. Johnson RL, Rothman AL, Xie J et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 1996; 272; 1668-1671.
68. Hahn H, Wojnowski L, Zimmer AM et al. Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorlin syndrome. Nat. Med. 1998; 4; 619-622.
69. Armstrong SJ, Duncan AW, Mott MG. Rhabdomyosarcoma associated with familial adenomatous polyposis. Pediatr. Radiol. 1991; 21; 445-446.
70. Hasegawa T, Matsuno Y, Niki T et al. Second primary rhabdomyosarcomas in patients with bilateral retinoblastoma: a clinicopathologic and immunohistochemical study. Am. J. Surg. Pathol. 1998; 22; 1351-1360.
71. Sobel RA, Woerner S. Rubinstein-Taybi syndrome and nasopharyngeal rhabdomyosarcoma. J. Pediatr. 1981; 99; 1000-1001.
72. Tassabehji M, Read AP, Newton VE et al. Waardenburg's syndrome patients have mutations in the human homologue of the Pax-3 paired box gene. Nature 1992; 355; 635-636.
73. Bisogno G, Murgia A, Mammi I et al. Rhabdomyosarcoma in a patient with cardio-facio-cutaneous syndrome. J. Pediatr. Hematol. Oncol. 1999; 21; 424-427.
74. Limwongse C, Schwartz S, Bocian M et al. Child with mosaic variegated aneuploidy and embryonal rhabdomyosarcoma. Am. J. Med. Genet. 1999; 82; 20-24.
75. Xu F, De Las Casas LE, Dobbs LJ Jr. Primary meningeal rhabdomyosarcoma in a child with hypomelanosis of Ito. Arch. Pathol. Lab. Med. 2000; 124; 762-765.
76. Meyer S, Kingston H, Taylor AM et al. Rhabdomyosarcoma in Nijmegen breakage syndrome: strong association with perianal primary site. Cancer Genet. Cytogenet. 2004; 154; 169-174.
77. Kratz CP, Holter S, Etzler J, et al. Rhabdomyosarcoma in patients with constitutional mismatch-repair-deficiency syndrome. J. Med. Genet. 2009; 46; 418-420.
78. Ruymann FB, Maddux HR, Ragab A et al. Congenital anomalies associated with rhabdomyosarcoma: an autopsy study of 115 cases. A report from the Intergroup Rhabdomyosarcoma Study Committee (representing the Children's Cancer Study Group, the Pediatric Oncology Group, the United Kingdom Children's Cancer Study Group, and the Pediatric Intergroup Statistical Center). Med. Pediatr. Oncol. 1988; 16; 33-39.
79. Bisogno G, Sotti G, Nowicki Y et al. Soft tissue sarcoma as a second malignant neoplasm in the pediatric age group. Cancer 2004; 100; 1758-1765.
80. Coffin CM. Gardner fibroma. In Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F eds. WHO classification of tumours of soft tissue and bone, 4th edn. Lyon, France: International Agency for Research on Cancer, 2013; 68.
81. Wehrli BM, Weiss SW, Yandow S et al. Gardner-associated fibromas (GAF) in young patients: a distinct fibrous lesion that identifies unsuspected Gardner syndrome and risk for fibromatosis. Am. J. Surg. Pathol. 2001; 25; 645-651.
82. Coffin CM, Hornick JL, Zhou H et al. Gardner fibroma: a clinicopathologic and immunohistochemical analysis of 45 patients with 57 fibromas. Am. J. Surg. Pathol. 2007; 31; 410-416.
83. Goldblum JR, Fletcher JA. Desmoid-type fibromatosis. In Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens Feds. WHO classification of tumours of soft tissue and bone, 4th edn. Lyon, France: International Agency for Research on Cancer, 2013; 72-73.
84. Levesque S, Ahmed N, Nguyen VH et al. Neonatal Gardner fibroma: a sentinel presentation of severe familial adenomatous polyposis. Pediatrics 2010; 126; e1599-e1602.
85. Clark SK, Johnson Smith TGP, Katz DE et al. Identification and progression of a desmoid precursor lesion in patients with familial adenomatous polyposis. Br. J. Surg. 1998; 85; 970-973.
86. Pho LN, Coffin CM, Burt RW. Abdominal desmoid in familial adenomatous polyposis presenting as a pancreatic cystic lesion. Fam. Cancer 2005; 4; 135-138.
87. Gardner EJ, Richards RC. Multiple cutaneous and subcutaneous lesions occurring simultaneously with hereditary polyposis and osteomatosis. Am. J. Hum. Genet. 1953; 5; 139-147.
88. Gardner EJ, Woolf CM, Shaffer JO. The inheritance of cancer involving different areas of the human gastrointestinal tract. J. Natl Cancer Inst. 1953; 13; 1089-1093.
89. Gardner EJ. Follow-up study of a family group exhibiting dominant inheritance for a syndrome including intestinal polyps, osteomas, fibromas and epidermal cysts. Am. J. Hum. Genet. 1962; 14; 376-390.
90. Naylor EW, Gardner EJ, Richards RC. Desmoid tumors and mesenteric fibromatosis in Gardner's syndrome: report of kindred 109. Arch. Surg. 1979; 114; 1181-1185.
91. Alman BA, Pajerski ME, Diaz-Cano S et al. Aggressive fibromatosis (desmoid tumor) is a monoclonal disorder. Diagn. Mol. Pathol. 1997; 6; 98-101.
92. Knudsen AL, Bulow S. Desmoid tumour in familial adenomatous polyposis: a review of literature. Fam. Cancer 2001; 1; 111-119.
93. Fallen T, Wilson M, Morlan B, Lindor NM. Desmoid tumors: a characterization of patients seen at Mayo Clinic 1976-1999. Fam. Cancer 2006; 5; 191-194.
94. Galiatsatos P, Foulkes WD. Familial adenomatous polyposis. Am. J. Gastroenterol. 2006; 101; 385-398.
95. Gebert C, Hardes J, Kersting C et al. Expression of beta-catenin and p53 are prognostic factors in deep aggressive fibromatosis. Histopathology 2007; 50; 491-497.
96. Escobar C, Munker R, Thomas JO et al. Update on desmoid tumors. Ann. Oncol. 2012; 23; 562-569.
97. Reitamo JJ, Scheinin TM, Hayry P. The desmoid syndrome: new aspects in the cause, pathogenesis and treatment of the desmoid tumor. Am. J. Surg. 1986; 151; 230-237.
98. Bertario L, Russo A, Sala P et al. Genotype and phenotype factors as determinants of desmoid tumors in patients with familial adenomatous polyposis. Int. J. Cancer 2001; 95; 102-107.
99. Okuno S. The enigma of desmoid tumors. Curr. Treat. Options Oncol. 2006; 7; 438-443.
100. Ng TL, Gown AM, Barry TS et al. Nuclear beta-catenin in mesenchymal tumors. Mod. Pathol. 2005; 18; 68-74.
101. Carlson JW, Fletcher CD. Immunohistochemistry for beta-catenin in the differential diagnosis of spindle cell lesions: analysis of a series and review of the literature. Histopathology 2007; 51; 509-514.
102. Fletcher JA, Naeem R, Xiao S et al. Chromosome aberrations in desmoid tumors. Trisomy 8 may be a predictor of recurrence. Cancer Genet. Cytogenet. 1995; 79; 139-143.
103. Bridge JA, Swarts SJ, Buresh C et al. Trisomies 8 and 20 characterize a subgroup of benign fibrous lesions arising in both soft tissue and bone. Am. J. Pathol. 1999; 154; 729-733.
104. Lazar AJ, Tuvin D, Hajibashi S et al. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am. J. Pathol. 2008; 173; 1518-1527.
105. Salas S, Chibon F, Noguchi T et al. Molecular characterization by array comparative genomic hybridization and DNA sequencing of 194 desmoid tumors. Genes Chromosom. Cancer 2010; 49; 560-568.
106. Gurbuz AK, Giardiello FM, Petersen GM et al. Desmoid tumours in familial adenomatous polyposis. Gut 1994; 35; 377-381.
107. Coffin CM. Editorial: making a difference. Pediatr. Dev. Pathol. 1998; 1; 177-178.
108. Gutmann DH, Aylsworth A, Carey JC et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997; 278; 51-57.
109. Cates JMM, Coffin CM. Neurogenic tumors of soft tissue. Pediatr. Dev. Pathol. 2012; 15; 62-107.
110. Rodriguez FJ, Folpe AL, Giannini C et al. Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems. Acta Neuropathol. 2012; 123; 295-319.
111. Antonescu CR, Brems H, Legius E, Woodruff JM. Neurofibroma (including variants). In Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F eds. WHO classification of tumours of soft tissue and bone, 4th edn. Lyon, France: International Agency for Research on Cancer, 2013; 174-176.
112. Nielsen GP, Antonescu CR, Lothe RA. Malignant peripheral nerve sheath tumor. In Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F eds. WHO classification of tumours of soft tissue and bone, 4th edn. Lyon, France: International Agency for Research on Cancer, 2013; 187-189.
113. Rosenbaum T, Patrie K, Ratner N. Neurofibromatosis type 1: genetic and cellular mechanisms of peripheral nerve tumor foundation. Neuroscientist 1997; 3; 412-420.
114. Ferner RE, Huson SM, Thomas N et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J. Med. Genet. 2007; 44; 81-88.
115. Riccardi VM. Von Recklinghausen neurofibromatosis. N. Engl. J. Med. 1981; 305; 1617-1627.
116. Le LQ, Liu C, Shipman T et al. Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development. Cancer Res. 2011; 71; 4686-4695.
117. Atherton DJ, Pitcher DW, Wells RS et al. A syndrome of various cutaneous pigmented lesions, myxoid neurofibromata and atrial myxoma: the NAME syndrome. Br. J. Dermatol. 1980; 103; 421-429.
118. Qualman SJ, Green WR, Brovall C et al. Neurofibromatosis and associated neuroectodermal tumors: a congenital neurocristopathy. Pediatr. Pathol. 1986; 5; 65-78.
119. Listernick R, Charrow J. Neurofibromatosis-1 in childhood. Adv. Dermatol. 2004; 20; 75-115.
120. Ferner RE. Neurofibromatosis 1 and neurofibromatosis 2: a twenty-first century perspective. Lancet Neurol. 2007; 6; 340-351.
121. Staser K, Yang FC, Clapp DW. Plexiform neurofibroma genesis: questions of NF1 gene dose and hyperactive mast cells. Curr. Opin. Hematol. 2010; 17; 287-293.
122. Lewis JJ, Brennan MF. Soft tissue sarcomas. Curr. Probl. Surg. 1996; 33; 817-872.
123. D'Agostino AN, Soule EH, Miller RH. Sarcomas of the peripheral nerves and somatic soft tissues associated with multiple neurofibromatosis (von Recklinghausen's disease). Cancer 1963; 16; 1015-1021.
124. Guccion JG, Enzinger FM. Malignant schwannoma associated with von Recklinghausen's neurofibromatosis. Virchows Arch. A Pathol. Anat. Histol. 1979; 383; 43-57.
125. Riccardi VM, Powell PP. Neurofibrosarcoma as a complication of von Recklinghausen neurofibromatosis. Neurofibromatosis 1989; 2; 152-165.
126. Ducatman BS, Scheithauer BW, Piepgras DG et al. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 1986; 57; 2006-2021.
127. Evans DGR, Baser ME, McGaughran J et al. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J. Med. Genet. 2002; 39; 311-314.
128. Ferner RE, Gutmann DH. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res. 2002; 62; 1573-1577.
129. McCaughan JA, Holloway SM, Davidson R et al. Further evidence of the increased risk for malignant peripheral nerve sheath tumour from a Scottish cohort of patients with neurofibromatosis type 1. J. Med. Genet. 2007; 44; 463-466.
130. Tucker T, Wolkenstein P, Revuz J et al. Association between benign and malignant peripheral nerve sheath tumors in NF1. Neurology 2005; 65; 205-211.
131. Bredella MA, Torriani M, Hornicek F et al. Value of PET in the assessment of patients with neurofibromatosis type 1. Am. J. Roentgenol. 2007; 189; 928-935.
132. Ducatman BS, Scheithauer BW, Piepgras DG et al. Malignant peripheral nerve sheath tumors in childhood. J. Neurooncol. 1984; 2; 241-248.
133. Stucky CC, Johnson KN, Gray RJ et al. Malignant peripheral nerve sheath tumors (MPNST): the Mayo Clinic Experience. Ann. Surg. Oncol. 2011; 19; 878-885.
134. Woodruff JM, Christensen WN. Glandular peripheral nerve sheath tumors. Cancer 1993; 72; 3618-3628.
135. Takeuchi A, Ushigome S. Diverse differentiation in malignant peripheral nerve sheath tumours associated with neurofibromatosis-1: an immunohistochemical and ultrastructural study. Histopathology 2001; 39; 298-309.
136. Coindre JM, Terrier P, Guillou L et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer 2001; 91; 1914-1926.
137. Watanabe T, Oda Y, Tamiya S et al. Malignant peripheral nerve sheath tumour arising within neurofibroma. An immunohistochemical analysis in the comparison between benign and malignant components. J. Clin. Pathol. 2001; 54; 631-636.
138. Liapis H, Marley EF, Lin Y et al. p53 and Ki-67 proliferating cell nuclear antigen in benign and malignant peripheral nerve sheath tumors in children. Pediatr. Dev. Pathol. 1999; 2; 377-384.
139. Zhou H, Coffin CM, Perkins SL et al. Malignant peripheral nerve sheath tumor: a comparison of grade, immunophenotype, and cell cycle/growth activation marker expression in sporadic and neurofibromatosis 1-related lesions. Am. J. Surg. Pathol. 2003; 27; 1337-1345.
140. Skuse GR, Kosciolek BA, Rowley PT. The neurofibroma in von Recklinghausen neurofibromatosis has a unicellular origin. Am. J. Hum. Genet. 1991; 49; 600-607.
141. Colman SD, Williams CA, Wallace MR. Benign neurofibromas in type 1 neurofibromatosis (NF1) shows somatic deletions of the NF1 gene. Nat. Genet. 1995; 11; 90-92.
142. Sawada S, Florell S, Purandare SM et al. Identification of NF1 mutations in both alleles of a dermal neurofibroma. Nat. Genet. 1996; 14; 110-112.
143. Serra E, Puig S, Otero D et al. Confirmation of a double-hit model for the NF1 gene in benign neurofibromas. Am. J. Hum. Genet. 1997; 61; 512-519.
144. McCarron KF, Goldblum JR. Plexiform neurofibroma with and without associated malignant peripheral nerve sheath tumor: a clinicopathologic and immunohistochemical analysis of 54 cases. Mod. Pathol. 1998; 11; 612-617.
145. Mertens F, Dal Cin P, De Wever I et al. Cytogenetic characterization of peripheral nerve sheath tumours: a report of the CHAMP study group. J. Pathol. 2000; 190; 31-38.
146. Mantripragada KK, de Stahl TD, Patridge C et al. Genome-wide high-resolution analysis of DNA copy number alterations in NF1-associated malignant peripheral nerve sheath tumors using 32K BAC array. Genes Chromosom. Cancer 2009; 48; 897-907.
147. Mosso ML, Castello M, Bellani FF et al. Neurofibromatosis and malignant childhood cancers: a survey in Italy, 1970-83. Tumori 1987; 73; 209-212.
148. Schneider M, Obringer AC, Zackai E et al. Childhood neurofibromatosis: risk factors for malignant disease. Cancer Genet. Cytogenet. 1986; 21; 347-354.
149. Barone JG, Massad CA, Parrott TS et al. Symptomatic tumors affecting the urinary tract in children and neurofibromatosis. J. Urol. 1995; 154; 1516-1517.
150. Poyhonen M, Niemela S, Herva R. Risk of malignancy and death in neurofibromatosis. Arch. Pathol. Lab. Med. 1997; 121; 139-143.
151. Bottillo I, Ahiquist T, Brekke H et al. Germline and somatic NF1 mutations in sporadic and NF1-associated malignant peripheral nerve sheath tumors. J. Pathol. 2009; 217; 693-701.
152. Upadhyaya M, Kluwe L, Spurlock G et al. Germline and somatic NF1 gene mutation spectrum in NF1-associated malignant peripheral nerve sheath tumors (MPNSTs). Hum. Mutat. 2008; 29; 74-82.
153. Meis JM, Enzinger FM, Martz KL et al. Malignant peripheral nerve sheath tumors (malignant schwannomas) in children. Am. J. Surg. Pathol. 1992; 16; 694-707.
154. Carli M, Ferrari A, Mattke A et al. Pediatric malignant peripheral nerve sheath tumor: the Italian and German soft tissue sarcoma cooperative group. J. Clin. Oncol. 2005; 23; 8422-8430.
155. De Raedt T, Brems H, Wolkenstein P et al. Elevated risk for MPNST in NF1 microdeletion patients. Am. J. Hum. Genet. 2003; 72; 1288-1292.
156. Williams V, Lucas J, Babcock M et al. Neurofibromatosis type 1 revisited. Pediatrics 2009; 123; 124-133.
157. Fletcher CD. Malignant peripheral nerve sheath tumours. Curr. Top. Pathol. 1995; 89; 333-354.
158. Lin BT, Weiss LM, Medeiros LJ. Neurofibroma and cellular neurofibroma with atypia: a report of 14 tumors. Am. J. Surg. Pathol. 1997; 21; 1443-1449.
159. MacCollin M, Chiocca EA, Evans DG et al. Diagnostic criteria for schwannomatosis. Neurology 2005; 64; 1838-1845.
160. Baser ME, Friedman JM, Evans DG. Increasing the specificity of diagnostic criteria for schwannomatosis. Neurology 2006; 66; 730-732.
161. Hulsebos TJ, Plomp AS, Wolterman RA et al. Germline mutation of INI1/SMARCB1 in familial schwannomatosis. Am. J. Hum. Genet. 2007; 80; 805-810.
162. Antonescu CR, Perry A, Woodruff JM. Schwannoma (including variants). In Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F eds. WHO classification of tumours of soft tissue and bone, 4th edn. Lyon, France: International Agency for Research on Cancer, 2013; 170-173.
163. Eldridge R. Central neurofibromatosis with bilateral acoustic neuroma. Adv. Neurol. 1981; 29; 57-65.
164. Kanter WR, Eldridge R, Fabricant R et al. Central neurofibromatosis with bilateral acoustic neuroma: genetic clinical and biochemical distinctions from peripheral neurofibromatosis. Neurology 1980; 30; 851-859.
165. Woodruff JM, Godwin TA, Erlandson RA et al. Cellular schwannoma: a variety of schwannoma sometimes mistaken for a malignant tumor. Am. J. Surg. Pathol. 1981; 5; 733-744.
166. Woodruff JM, Scheithauer BW, Kurtkaya-Yapicier O et al. Congenital and childhood plexiform (multinodular) cellular schwannoma: a troublesome mimic of malignant peripheral nerve sheath tumor. Am. J. Surg. Pathol. 2003; 27; 1321-1329.
167. Nascimento AF, Fletcher CD. The controversial nosology of benign nerve sheath tumors: neurofilament protein staining demonstrates intratumoral axons in many sporadic schwannomas. Am. J. Surg. Pathol. 2007; 31; 1363-1370.
168. Diebold R, Bartelt-Kirbach B, Evans DG et al. Sensitive detection of deletions of one or more exons in the neurofibromatosis type 2 (NF2) gene by multiplexed gene dosage polymerase chain reaction. J. Mol. Diagn. 2005; 7; 97-104.
169. Lasota J, Fetsch JF, Wozniak A et al. The neurofibromatosis type 2 gene is mutated in perineurial cell tumors: a molecular genetic study of eight cases. Am. J. Pathol. 2001; 158; 1223-1229.
170. Pitchford CW, Schwartz HS, Atkinson JB et al. Soft tissue perineurioma in a patient with neurofibromatosis type 2: a tumor not previously associated with the NF2 syndrome. Am. J. Surg. Pathol. 2006; 30; 1624-1629.
171. Harder A, Wesemann M, Hagel C et al. Hybrid neurofibroma/schwannoma is overrepresented among schwannomatosis and neurofibromatosis patients. Am. J. Surg. Pathol. 2012; 36; 702-709.
172. Christiaans I, Kanter SB, Brink HC et al. Germline SMARCB1 mutation and somatic NF2 mutations in familial multiple meningioma. J. Med. Genet. 2011; 48; 93-97.
173. Patil S, Perry A, MacCollin M et al. Immunohistochemical analysis supports a role for INI1/SMARCB1 in hereditary forms of schwannomas, but not in solitary, sporadic schwannomas. Brain Pathol. 2008; 18; 517-519.
174. Shishiba T, Niimura M, Ohtsuka F et al. Multiple cutaneous neurilemmomas as a skin manifestation of neurilemmomatosis. J. Am. Acad. Dermatol. 1984; 10; 744-754.
175. Rizzo D, Freneaux P, Brisse H et al. SMARCB1 deficiency in tumors from the peripheral nervous system: a link between schwannomas and rhabdoid tumors? Am. J. Surg. Pathol. 2012; 36; 964-972.
176. Antonescu CR, Stratakis CA, Woodruff JM. Melanotic schwannoma. In Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F eds. WHO classification of tumours of soft tissue and bone, 4th edn. Lyon, France: International Agency for Research on Cancer, 2013; 173-174.
177. Carney JA. Psammomatous melanotic schwannoma. A distinctive, heritable tumor with special associations, including cardiac myxoma and the Cushing syndrome. Am. J. Surg. Pathol. 1990; 14; 206-222.
178. Stratakis CA, Kirschner LS, Carney JA. Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. J. Clin. Endocrinol. Metab. 2001; 86; 4041-4046.
179. White FV, Dehner LP, Belchis DA et al. Congenital disseminated malignant rhabdoid tumor: a distinct clinicopathologic entity demonstrating abnormalities of chromosome 22q11. Am. J. Surg. Pathol. 1999; 23; 249-256.
180. Fernandez C, Bouvier C, Sevenet N et al. Congenital disseminated malignant rhabdoid tumor and cerebellar tumor mimicking medulloblastoma in monozygotic twins: pathologic and molecular diagnosis. Am. J. Surg. Pathol. 2002; 26; 266-270.
181. Hollmann TJ, Hornick JL. INI1-deficient tumors: diagnostic features and molecular genetics. Am. J. Surg. Pathol. 2011; 35; e47-e63.
182. Alaggio R, Coffin CM, Vargas SO. Soft tissue tumors of uncertain origin. Pediatr. Dev. Pathol. 2012; 15; 267-305.
183. Oda Y, Biegel JA. Extrarenal rhabdoid tumor. In Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F eds. WHO classification of tumours of soft tissue and bone, 4th edn. Lyon, France: International Agency for Research on Cancer, 2013; 228-229.
184. Versteege I, Sevenet N, Lange J et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 1998; 394; 203-206.
185. Biegel JA, Zhou JY, Rorke LB et al. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res. 1999; 59; 74-79.
186. Sevenet N, Lellouch-Tubiana A, Schofield D et al. Spectrum of hSNF5/INI1 somatic mutations in human cancer and genotype-phenotype correlations. Hum. Mol. Genet. 1999; 8; 2359-2368.
187. Sevenet N, Sheridan E, Amram D et al. Constitutional mutations of the hSNF5/INI1 gene predispose to a variety of cancers. Am. J. Hum. Genet. 1999; 65; 1342-1348.
188. Biegel JA, Fogelgren B, Wainwright LM et al. Germline INI1 mutation in a patient with a central nervous system atypical teratoid tumor and renal rhabdoid tumor. Genes Chromosom. Cancer 2000; 28; 31-37.
189. Proust F, Laquerriere A, Constantin B et al. Simultaneous presentation of atypical teratoid/rhabdoid tumor in siblings. J. Neurooncol. 1999; 43; 63-70.
190. Lee HY, Yoon CS, Sevenet N et al. Rhabdoid tumor of the kidney is a component of the rhabdoid predisposition syndrome. Pediatr. Dev. Pathol. 2002; 5; 395-399.
191. Fujisawa H, Takabatake Y, Fukusato T et al. Molecular analysis of the rhabdoid predisposition syndrome in a child: a novel germline hSNF5/INI1 mutation and absence of c-myc amplification. J. Neurooncol. 2003; 63; 257-262.
192. Perry A. Familial posterior fossa brain tumor syndrome of infancy. Adv. Anat. Pathol. 2006; 13; 198-199.
193. Bourdeaut F, Lequin D, Brugieres L et al. Frequent hSNF5/INI1 germline mutations in patients with rhabdoid tumor. Clin. Cancer Res. 2011; 17; 31-38.
194. Harris TJ, Donahue JE, Shur N et al. Case 168: rhabdoid predisposition syndrome - familial cancer syndromes in children. Radiology 2011; 259; 298-302.
195. Schneppenheim R, Fruhwald MC, Gesk S et al. Germline nonsense mutation
196. Eaton KW, Tooke LS, Wainwright LM et al. Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumors. Pediatr. Blood Cancer 2011; 56; 7-15.
197. Sahdev I, James-Herry A, Scimeca P et al. Concordant rhabdoid tumor of the kidney in a set of identical twins with discordant outcomes. J. Pediatr. Hematol. Oncol. 2003; 25; 491-494.
198. Fruhwald MC, Hasselblatt M, Wirth S et al. Non-linkage of familial tumors to SMARCB1 implies a second locus for the rhabdoid tumor predisposition syndrome. Pediatr. Blood Cancer 2006; 47; 273-278.
199. Forest F, David A, Arrufat S et al. Conventional chondrosarcoma in a survivor of rhabdoid tumor: enlarging the spectrum of tumors associated with SMARCB1 germline mutations. Am. J. Surg. Pathol. 2012; 36; 1892-1896.
200. Jackson EM, Shaikh TH, Zhang F et al. Atypical teratoid/rhabdoid tumor in a patient with Beckwith-Wiedemann syndrome. Am. J. Med. Genet. A 2007; 143; 1767-1770.
201. Jackson EM, Shaikh TH, Gururangan S et al. High-density single nucleotide polymorphism array analysis in patients with germline deletions of 22q11.2 and malignant rhabdoid tumor. Hum. Genet. 2007; 122; 117-127.
202. Lafay-Cousin L, Payne E, Strother D, Chernos J, Chan M, Bernier FP. Goldenhar phenotype in a child with distal 22q11.2 deletion and intracranial atypical teratoid rhabdoid tumor. Am. J. Med. Genet. A 2009; 149A; 2855-2859.
203. Sathyamoorthi S, Morales J, Bermudez J et al. Array analysis and molecular studies of INI1 in an infant with deletion 22q13 (Phelan-McDermid syndrome) and atypical teratoid/rhabdoid tumor. Am. J. Med. Genet. A 2009; 149A; 1067-1069.